SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO4917523 AND AN INTRAVENOUS TRACER DOSE OF [13C]-LABELED RO4917523 IN HEALTHY MALE VOLUNTEERS

Completed

• Conditions: anxiety; depressive disorders; 10027946

• Registration Number: NL-OMON35686
• Lead Sponsor: F Hoffmann-La Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Age: 18 - 65 years (inclusive)
BMI: 18.0 - 32.0 kg/m2 (inclusive)
Gender: healthy male subjects

Exclusion Criteria

Suffering from: hepatitus B, cancer or HIV/AIDS. In case of participation in another study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior to the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>safety<br /><br>tolerability<br /><br>absorption, distribution, metabolizing and elimination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.a.</p><br>